Biofrontera Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $12.0 million (+32.9% year over year) and diluted EPS of -$0.05. It usually reports 13–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 13–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
12
+32.9%
|
-1
+88.7%
|
-0.05
+91.2%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
10
+17.4%
|
-5
-13.1%
|
-0.41
+12.8%
|
|
Jan 13, 2026
13 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
17
+36.2%
|
6
+504.0%
|
0.48
+361.8%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
7
-22.5%
|
-7
-17.3%
|
-0.62
+36.7%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
9
+15.2%
|
-5
-1971.6%
|
-0.57
-1040.0%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
9
+8.5%
|
-4
+59.7%
|
-0.47
+83.7%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
9
+1.3%
|
-6
+10.6%
|
-0.98
+78.9%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BFRI (Nasdaq), BFRIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1858685
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.